Sebert M, Freiman L, Chaffaut C, Guerci A, et al. Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 2024;38:918-922.
PMID: 38368440